Fred Lublin

Jan 8, 2025 | neurologylive.com | Fred Lublin |Isabella Ciccone

Current phenotyping in multiple sclerosis (MS) has largely focused on clinical classifications, such as relapsing-remitting, secondary progressive, and primary progressive forms, based on the patient’s presentation of the disease. While this approach is useful, it has limitations, as it fails to fully capture the complexity and heterogeneity of MS.

Jun 25, 2024 | mdedge.com | Fred Lublin

Data have shown that CD20-expressing B cells are crucial to the pathogenesis of multiple sclerosis (MS). First approved by the US Food and Drug Administration for MS in 2017, anti-CD20 monoclonal antibody therapies including ocrelizumab, ofatumumab, and ublituximab have proven effective at controlling the symptoms of relapsing-remitting MS (RRMS). In this ReCAP, Dr Fred D.

May 30, 2024 | neurologylive.com | Jeffrey Wilken |Fred Lublin |Brian Hutchinson |Robert Motl

May 30, 2024Host Jeffrey Wilken, PhD, chats with Fred Lublin, MD; Brian Hutchinson, PT, MSCS; and Robert Motl, PhD, about the second day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.

Oct 18, 2023 | journals.sagepub.com | Fred Lublin

Cite articleIf you have citation software installed, you can download article citation data to the citation manager of your choiceSelect your citation manager software:Share optionsShare this articleShare with emailEMAIL ARTICLE LINKShare on social mediaShare access to this articleSharing links are not relevant where the article is open access and not available if you do not have a subscription. For more information view the Sage Journals article sharingpage.